💉

LUPIN

Bags USFDA Nod for 2 Key Diabetes Drugs!

has secured USFDA approval for: 🔹 Liraglutide Injection (bioequivalent to Victoza®) – used to control blood sugar in type 2 diabetes; U.S. sales: $458M 🔹 Glucagon for Injection (bioequivalent to Eli Lilly’s Glucagon) – emergency treatment for severe hypoglycemia; U.S. sales: $124M 📍Both will be manufactured at Lupin’s Nagpur injectable facility. Lupin strengthens its U.S. diabetes portfolio with these high-value approvals. 💪🌎